reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesasenapine transdermal and olanzapine both increase sedation. Use Caution/Monitor.atomoxetineatomoxetine and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesatracuriumatracurium decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atracurium decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropineatropine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IMolanzapine increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atropine IV/IM decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.atropine IV/IM decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.avapritinibolanzapine will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.avapritinib and olanzapine both increase sedation. Use Caution/Monitor.axitinibolanzapine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.azelastineazelastine and olanzapine both increase sedation. Use Caution/Monitor.azithromycinazithromycin increases toxicity of olanzapine by QTc interval. Use Caution/Monitor.baclofenbaclofen and olanzapine both increase sedation. Use Caution/Monitor.bedaquilineolanzapine and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybelladonna alkaloidsbelladonna alkaloids decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna alkaloids decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.belladonna and opiumbelladonna and opium and olanzapine both increase sedation. Use Caution/Monitor.belladonna and opium decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.belladonna and opium decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benazeprilolanzapine, benazepril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypotensive effects.benperidolbenperidol and olanzapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.benperidol and olanzapine both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen and olanzapine both increase sedation. Use Caution/Monitor.benzphetamineolanzapine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benztropineolanzapine increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .brexanolonebrexanolone, olanzapine. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and olanzapine both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and olanzapine both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and olanzapine both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and olanzapine both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and olanzapine both increase sedation. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and olanzapine both increase sedation. Use Caution/Monitor.buprenorphine subdermal implantbuprenorphine subdermal implant and olanzapine both increase sedation. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and olanzapine both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionolanzapine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.buprenorphine, long-acting injection and olanzapine both increase sedation. Use Caution/Monitor.butabarbitalbutabarbital will decrease the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.butabarbital and olanzapine both increase sedation. Use Caution/Monitor.butalbitalbutalbital will decrease the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.butalbital and olanzapine both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and olanzapine both increase sedation. Use Caution/Monitor.caffeineolanzapine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.cannabidiolcannabidiol, olanzapine. affecting hepatic enzyme CYP1A2 metabolism. Modify Therapy/Monitor Closely. Owing to the potential for both CYP1A2 induction and inhibition with the coadministration of CYP1A2 substrates and cannabidiol, consider reducing dosage adjustment of CYP1A2 substrates as clinically appropriate.captoprilolanzapine, captopril. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure.carbamazepinecarbamazepine will decrease the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.carbinoxaminecarbinoxamine and olanzapine both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and olanzapine both increase sedation. Use Caution/Monitor.chloral hydratechloral hydrate and olanzapine both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and olanzapine both increase sedation. Use Caution/Monitor.chloroquinechloroquine increases toxicity of olanzapine by QTc interval. Use Caution/Monitor.chlorpheniraminechlorpheniramine and olanzapine both increase sedation. Use Caution/Monitor.chlorpromazinechlorpromazine and olanzapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and olanzapine both increase sedation. Use Caution/Monitor.chlorpropamideolanzapine, chlorpropamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.chlorzoxazonechlorzoxazone and olanzapine both increase sedation. Use Caution/Monitor.cigarette smokingcigarette smoking will decrease the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.cimetidinecimetidine will increase the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.cinnarizinecinnarizine and olanzapine both increase sedation. Use Caution/Monitor.ciprofloxacinciprofloxacin will increase the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Olanzapine plasma concentrations may be elevated, increasing the risk of adverse reactions such as orthostatic hypotension or sedation. It is important to use caution and observe patient and adjust the olanzapine dosage as needed.cisatracuriumcisatracurium decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cisatracurium decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.clemastineclemastine and olanzapine both increase sedation. Use Caution/Monitor.clobazamolanzapine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineolanzapine and clomipramine both increase sedation. Use Caution/Monitor.olanzapine and clomipramine both increase QTc interval. Use Caution/Monitor.clonazepamclonazepam and olanzapine both increase sedation. Use Caution/Monitor.clonidineclonidine, olanzapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateclorazepate and olanzapine both increase sedation. Use Caution/Monitor.clozapineclozapine and olanzapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.clozapine and olanzapine both increase sedation. Use Caution/Monitor.codeinecodeine and olanzapine both increase sedation. Use Caution/Monitor.cyclizinecyclizine and olanzapine both increase sedation. Use Caution/Monitor.cyclizine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclizine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclobenzaprinecyclobenzaprine and olanzapine both increase sedation. Use Caution/Monitor.cyclobenzaprine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclobenzaprine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyproheptadinecyproheptadine and olanzapine both increase sedation. Use Caution/Monitor.dantrolenedantrolene and olanzapine both increase sedation. Use Caution/Monitor.daridorexantolanzapine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.darifenacin decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.dasatinibdasatinib and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesdeferasiroxdeferasirox will increase the level or effect of olanzapine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.desipramineolanzapine and desipramine both increase sedation. Use Caution/Monitor.olanzapine and desipramine both increase QTc interval. Use Caution/Monitor.deutetrabenazineolanzapine and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.olanzapine and deutetrabenazine both increase sedation. Use Caution/Monitor.deutetrabenazine and olanzapine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine and olanzapine both increase sedation. Use Caution/Monitor.dexfenfluramineolanzapine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidinedexmedetomidine and olanzapine both increase sedation. Use Caution/Monitor.dexmethylphenidateolanzapine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetamineolanzapine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextromethorphandextromethorphan, olanzapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dextromoramidedextromoramide and olanzapine both increase sedation. Use Caution/Monitor.diamorphinediamorphine and olanzapine both increase sedation. Use Caution/Monitor.diazepamdiazepam and olanzapine both increase sedation. Use Caution/Monitor.dicyclominedicyclomine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.dicyclomine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diethylpropionolanzapine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalindifelikefalin and olanzapine both increase sedation. Use Caution/Monitor.difenoxin hcldifenoxin hcl and olanzapine both increase sedation. Use Caution/Monitor.dihydroergotaminedihydroergotamine, olanzapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dimenhydrinatedimenhydrinate and olanzapine both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and olanzapine both increase sedation. Use Caution/Monitor.diphenhydramine decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.diphenhydramine decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.olanzapine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diphenoxylate hcldiphenoxylate hcl and olanzapine both increase sedation. Use Caution/Monitor.dipipanonedipipanone and olanzapine both increase sedation. Use Caution/Monitor.dobutamineolanzapine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dofetilidedofetilide increases toxicity of olanzapine by QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances.dolasetrondolasetron and olanzapine both increase QTc interval. Use Caution/Monitor.donepezildonepezil and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesdopamineolanzapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexamineolanzapine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinolanzapine and dosulepin both increase sedation. Use Caution/Monitor.doxepinolanzapine and doxepin both increase sedation. Use Caution/Monitor.doxepin and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesdoxylaminedoxylamine and olanzapine both increase sedation. Use Caution/Monitor.droperidoldroperidol and olanzapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.droperidol and olanzapine both increase sedation. Use Caution/Monitor.efavirenzefavirenz and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instanceseletriptaneletriptan, olanzapine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability,